DURECT Stock Price. Everything You Need To Know About The DURECT Stock!
DURECT Corp., a Cupertino, California-based company, is focused on advancing innovative and potentially life-saving investigational therapies through its Epigenetic Regulator Program. With a team of 79 full-time employees, the company has been in operation since its IPO on 2000-09-28.
DURECT Corp.’s product candidates include DUR-928 oral for metabolic and lipid disorders, and DUR-928 injectable for acute organ injuries. The firm also has several other commercial product candidates, including POSIMIR, PERSERIS, and Methydur Sustained Release Capsules.
The company is currently conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH)) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is the company’s lead product candidate, and is an endogenous sulfated oxysterol and an epigenetic regulator.
DURECT Corp. is also focused on drug delivery technology and has developed the SABER and CLOUD Bioerodible Injectable Depot Systems. The SABER system uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. The CLOUD system is a class of bioerodible injectable depot technology.
Keeping track of the latest developments in the stock market can provide valuable insights to investors. While it is important to conduct thorough research before investing, staying informed about factors such as stocks share price today, premarket trends, and market cap can help investors make informed decisions. By staying up-to-date, investors can better navigate the dynamic investment landscape and stay ahead of the game.
DURECT Stock Price. Everything You Need To Know About The DURECT Stock! performance
- Employees 79
- Company HQ Cupertino
- Website http://www.durect.com/
- DRRX Asset Type Common Stock
- DRRX Market Capitalization 29.6M
- Earnings Per Share -1.2
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you looking to invest in promising stocks from Malaysia, Thailand, Indonesia, or Vietnam? Look no further than DURECT Corp. With its cutting-edge research and development in pharmaceutical products, DURECT offers a compelling investment opportunity for retail investors. As a renowned investment platform, Zorion provides you with insights and recommendations to make informed decisions regarding your investments. We understand the importance of knowledge in investments, which is why we offer access to resources and educational materials to enhance your investment knowledge further. With Zorion and DURECT Corp., you can confidently navigate the stock market and maximize your investment potential. Start your investment journey today with Zorion and take advantage of the exciting opportunities offered by DURECT Corp.
